Advertisement

Blood Platelets, Aspirin and Prevention of Vascular Disease

  • Giovanni de Gaetano
  • Chiara Cerletti
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 177)

Abstract

“In 40 years as a general practitioner, I have been especially interested in the possibility that some simple and harmless agent may be effective against the two major causes of death and disability among the persons who have most to contribute to our civilization. When aspirin appeared to offer such protection, I urged my friends and patients to adopt the practice of taking aspirin, one or two 5 gr. tablets daily. Surely the practice could do no harm. It might prove life-saving. To date, approximately 8,000 men have adopted this regime, with a surprising result. Not a single case of detectable coronary or cerebral thrombosis has occurred among patients who faithfully have adhered to this regime. Sufficient time has elapsed since the start of this program for me to report that aspirin administration offers a safe and sure method of prophylaxis against thrombosis” (Craven, 1956).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–331.CrossRefGoogle Scholar
  2. Beaumont JL, Caen J, Bernard J. Action hémorrhagipare de racide acétylsalicylique au cours des maladies du sang. Bull Soc Med Hop Paris 1955; 71: 1087.PubMedGoogle Scholar
  3. Buczko W, de Gaetano G, Franco R, Donati MB. Biological properties of dialysable peptides derived from plasmin digestion of bovine fibrinogen preparations. Thromb Diath Haemorrh 1976; 35: 651–657.Google Scholar
  4. Cerletti C, Gambino MC, Garattini S, de Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclo-oxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest 1986; 78: 323–326.CrossRefGoogle Scholar
  5. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J 1956; 75: 38–44.Google Scholar
  6. de Gaetano G. Primary prevention of vascular disease by aspirin. Lancet 1988; 1: 1093–1094.CrossRefGoogle Scholar
  7. de Gaetano G, Cerletti C, Bertelè V. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet 1982; 11: 974–977.CrossRefGoogle Scholar
  8. de Gaetano G, Cerletti C, Dejana E, Latini R, Villa S. The “aspirin dilemma”: new points for discussion. Thromb Haemost 1984; 52: 215.PubMedGoogle Scholar
  9. de Gaetano G, Cerietti C, Dejana E, Latini R. Platelets and vascular occlusion. Pharmacology of platelet inhibition in humans: Implication sof the salicylate-aspirin interaction. Circulation 1985; 72: 1185–1193.CrossRefGoogle Scholar
  10. Evans G, Packham MA, Nishizawa EE, Mustard JF, Murphy EA. The effect of acetylsalicylic acid on platelet function. J Exp Med 1968; 128: 887–94.CrossRefGoogle Scholar
  11. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts II LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during administration of aspirin in man. J Clin Invest 1983; 71: 676–88.CrossRefGoogle Scholar
  12. Gambino MC, Passaghe S, Chen ZM, Bucchi F, Gori G, Latini R, de Gaetano G, Cerletti C. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclo-oxygenase activity is reduced by portacaval shunt in rats. J Pharmacol Exp Ther 1988; 245: 287–290.PubMedGoogle Scholar
  13. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994–24.CrossRefGoogle Scholar
  14. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,189 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–360. •Google Scholar
  15. Kocsis JJ, Hernandovich J, Silver MJ, Smith JB, Ingerman C. Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins 1973; 3: 141–44.CrossRefGoogle Scholar
  16. Marcus AJ. Aspirin and thromboembolism: A possible dilemma. N Engl J Med 1977; 297: 1284–85.CrossRefGoogle Scholar
  17. Moncada S, Vane JR, Arachidonic acid metabolites and interactions between platelets and blood-vessel wall. N Engl J Med 1979; 300: 1142–1147.CrossRefGoogle Scholar
  18. Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296:525.Google Scholar
  19. O’ Brien JR. Effects of salicylates on human platelets. Lancet 1968; i:779–83.Google Scholar
  20. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–1372.CrossRefGoogle Scholar
  21. Pedersen AK, FitzGerald GA. A dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclo-oxygenase. N Engl J Med 1984; 311: 1206–1211.CrossRefGoogle Scholar
  22. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313–316.CrossRefGoogle Scholar
  23. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Nati Acad Sci USA1975; 72: 3073–76.Google Scholar
  24. Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367–374.CrossRefGoogle Scholar
  25. Silver MJ. Mechanisms of hemostasis and therapy of thrombosis:New concepts based on the metabolism of arachidonic acid by platelets and endothelial cells. Adv Pharmacol Chemother 1981; 18: 1–47.CrossRefGoogle Scholar
  26. Smith JB, Willis AL. Aspirin selectivity inhibits prostaglandin production in human platelets. Nature New Biol 1971; 231: 235–37.CrossRefGoogle Scholar
  27. Steering Committee of the Physicians’ Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physician’s health study. N Engl J Med 1988; 318: 262–264.CrossRefGoogle Scholar
  28. Villa S, de Gaetano G. Prostacyclin-like activity in rat vascular tissues. Fast, long-lasting inhibition by treatment with lysine acetylsalicylate. Prostaglandins 1977; 14: 1117–24.CrossRefGoogle Scholar
  29. Weiss HJ, Aledort LM. Impaired platelet connective-tissue interaction in man after aspirin ingestion. Lancet 1967; 2: 495–497.CrossRefGoogle Scholar
  30. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA Jr. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800–805.CrossRefGoogle Scholar
  31. Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547–51.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Giovanni de Gaetano
    • 1
  • Chiara Cerletti
    • 1
  1. 1.Istituto di Ricerche Farmacologiche Mario NegriConsorzio Mario Negri SudSanta Maria ImbaroItaly

Personalised recommendations